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Abstract: Deficits in neuronal structure are consistently associated with neurodevelopmental illnesses
such as autism and schizophrenia. Nonetheless, the inability to access neurons from clinical patients
has limited the study of early neurostructural changes directly in patients’ cells. This obstacle has
been circumvented by differentiating stem cells into neurons, although the most used methodologies
are time consuming. Therefore, we recently developed a relatively rapid (~20 days) protocol for
transdifferentiating human circulating monocytes into neuronal-like cells. These monocyte-derivedneuronal-like cells (MDNCs) express several genes and proteins considered neuronal markers, such
as MAP-2 and PSD-95. In addition, these cells conduct electrical activity. We have also previously
shown that the structure of MDNCs is comparable with that of human developing neurons (HDNs)
after 5 days in culture. Moreover, the neurostructure of MDNCs responds similarly to that of HDNs
when exposed to colchicine and dopamine. In this manuscript, we expanded our characterization
of MDNCs to include the expression of 12 neuronal genes, including tau. Following, we compared
three different tracing approaches (two semi-automated and one automated) that enable tracing
using photographs of live cells. This comparison is imperative for determining which neurite
tracing method is more efficient in extracting neurostructural data from MDNCs and thus allowing
researchers to take advantage of the faster yield provided by these neuronal-like cells. Surprisingly, it
was one of the semi-automated methods that was the fastest, consisting of tracing only the longest
primary and the longest secondary neurite. This tracing technique also detected more structural
deficits. The only automated method tested, Volocity, detected MDNCs but failed to trace the
entire neuritic length. Other advantages and disadvantages of the three tracing approaches are also
presented and discussed.
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1. Introduction
Neurodevelopmental disorders such as autism and schizophrenia are relatively common alignments [1,2] caused by a complex combination of environmental and genetic
factors. Unfortunately, treatment and diagnostic methods for these illnesses remain unsatisfactory. It is therefore not surprising that the search for biomarkers is intense [3–8].
However, a crucial step in the development of biomarkers and improvement of treatment
as well as diagnosis for any illness is understanding its pathophysiology.
One of the many challenges researchers face when studying neurodevelopmental
disorders is that they are diagnosed once most neurodevelopmental stages have been
completed. For instance, schizophrenia is diagnosed in late adolescence or early adulthood.
Autism is often recognized earlier in life but still too late to study neuronal processes such
as neurite formation, neuronal polarization and pruning of neuronal extensions. These
neurodevelopmental processes are of particular importance, as the neuronal structure has
been consistently associated with the pathophysiology of schizophrenia and autism [9–13].
It is therefore possible that studying early neurostructural rearrangements directly in
cells from patients with autism or schizophrenia would lead to a better understanding of
its pathophysiology.
An additional challenge when ascertaining neurodevelopmental disorders is the
accessibility of neurons coming directly from clinical patients. This obstacle has been
circumvented by several different methods. The collection of olfactory neuroepithelial cells
(ONCs) is the only approach presently available that provides access to mature neurons [14].
It also delivers glial, epithelial and neuroprogenitor cells as well as neurons at different
stages of differentiation [15,16]. In order to access ONCs, a qualified otorhinolaryngologist
has to perform a biopsy of the olfactory mucosa [16]. This invasive procedure has limited
the use of ONCs. In addition, concerns have been raised about the reproducibility of data
when using olfactory mucosa, as biopsies from the same individual can deliver variable
results [15,16]. Another approach that circumvents the limited access of neurons coming
directly from patients is the use of mesenchymal stem cells (MSCs). MSCs can be rapidly
differentiated into neuronal-like cells in vitro [17]. However, the scarce use of MSCs in the
study of psychiatric and neurologic disorders appears to be due to difficulties in retrieving
MSCs. Obtaining MSCs, often if not always, requires a biopsy [18], which is a surgical
procedure that requires consultation with a specialist. There is also another characteristic
of MSCs that has determined its fate in research: the fact that MSCs do not trigger an
immunological reaction. Such an attribute makes this type of stem cells an excellent tool
for cellular transplant [18]. On the other hand, to study neurodevelopmental disorders, the
most common stem cells currently used are induced pluripotent stem cells (IPSCs). IPSCs
allow researchers to develop different types of neurons with sophisticated neuropils [19].
Even brain organoids that resemble aspects of early brain development can be generated
using IPSCs [19]. Unfortunately, generating IPSCs requires altering the cell’s genome (reprograming) [20,21], which can become a confounder when studying illnesses with poorly
understood genetic predispositions, such as autism and schizophrenia [22]. IPSCs have
also been criticized because of difficulties in reproducibility [23,24]. Moreover, the transformation of somatic cell to differentiated neuron is expensive and time consuming [15].
Not surprisingly, published manuscripts involving IPSCs and neurodevelopmental disorders comprise rather small cohorts. Another emerging methodology consists of directly
reprogramming somatic cells, often fibroblasts, directly into neurons [25,26]. This approach, known as induced neurons (iNs), bypasses the need for dedifferentiation but still
requires altering the cell’s genome [25,26]. The potential confounding effects of reprograming and the need to show reproducible results when studying neurodevelopmental
disorders remain. However, iNs are becoming a promising alternative for regenerative
medicine [27]. A faster approach for obtaining neuronal-like cells that completely avoids
genetic reprogramming is transdifferentiation of somatic cells.
We have recently developed a methodology for transdifferentiating human circulating
monocytes into neuronal-like cells in only 20 days [28]. These monocyte-derived-neuronal-
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like cells (MDNCs) express several genes and proteins considered neuronal markers.
Among the genes and proteins present in MDNCs are NeuN and PSD-95, considered
markers for mature neurons. However, MDNCs also express markers of immature neurons
such as nestin. Moreover, these cells are not yet committed to developing into any specific
neuronal type and instead express markers for glutamatergic, dopaminergic, GABAergic
and serotoninergic neurons. Of particular importance for the study of the neuronal structure is the expression of microtubule associated protein 2 (MAP-2) [28], as this protein is a
marker for dendrites [29,30]. Tau is another relevant neuronal protein, as it is an axonal
marker [29,30]. Immature neuronal extensions that have not yet developed into either
axons or dendrites are called neurites [31]. During early stages of neuronal development,
MAP-2 is present in all neurites and in the cell soma [29,30]. We have previously shown
that MDNCs express MAP-2 in all its extensions as well as in the soma [28]. While expression of tau in MDNCs is still to be proven, the information currently available indicates
that MDNCs extend neurites that have not yet developed into either dendrites or axons.
However, even at this early stage of neurodevelopment, we have shown that MDNCs
conduct electrical activity [28].
In a prior publication, we directly compared the structure of MDNCs with that of
human developing neurons (after 5 days in culture) as well as with that of differentiated
human neuroblastoma cells [28]. The structure of these three different neuronal cell types
was similar [28]. Perhaps more important for the study of schizophrenia and autism is
that the structure of MDNCs responds similarly to human neurons and neuroblastoma
cells when exposed to dopamine and colchicine [28]. Therefore, MDNCs allow us to study
some aspects of the neuronal structure that take place during early development directly in
patients’ cells that carry the genetic predisposition to illnesses such as schizophrenia and
autism. This opens the possibility of starting to unveil the pathophysiology of such neurodevelopmental disorders. While other neurodevelopmental disorders such as attention
deficit hyperactivity disorder (ADHD) [32], bipolar disorder [33] and others can also be
studied using MDNCs, here we emphasize autism and schizophrenia because deficits in
the neuronal structure are consistently found [9–13].
Neurite outgrowth is a key neuronal feature, and therefore characterizing neurites is
important for understanding MDNCs’ neuronal properties and their application in disease
and pharmacology research. Neurites are numerous, and accurate measurements through
individual neurite tracing are labor-intensive. Therefore, in order to take advantage of
this faster yield of neuronal-like cells, an efficient neurite tracing method is critical for
extracting neurostructural data from MDNCs. The current available options can be divided
into two general tracing methodologies: automated and semi-automated. Most automated
alternatives are similar. They rely on software capable of detecting neurons stained with a
fluorochrome. Tagged cells are automatically traced. The output of such softwares is faster
than semi-automated methods, as these latter options require the researcher to select the
cell to be traced and then identify the beginning and end of the neurite of interest. One of
the advantages of semi-automated methods is that researchers have more flexibility when
deciding which cells to trace, as they are not bound by the expression of a specific marker.
Another advantage is that immunofluorescence or the expression of a fluorescent marker
such as green fluorescent protein (GFP) can be avoided. These techniques are not always
desirable, as both can lead to cellular damage [34,35].
Postmortem studies indicate that defects in the neuronal structure of patients with
neurodevelopmental disorders are subtle [9–13]. Thus, avoiding immunofluorescence or
the expression of a fluorescent marker is advantageous, as these techniques could mask
inconspicuous defects [34,35]. Another strategy for minimizing structural confounders is
using each neuronal-like cell as its own control. For this purpose, cells are identified and
photographed before receiving any treatment. Then, after treatment with the compound
to be tested and once the desired incubation time has passed, the exact same cells are
again identified and photographed. Structural differences in the same cells before and
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after treatment are reported. We used this approach to determine the structural effects of
colchicine and dopamine on MDNCs [28].
In order to avoid the use of fluorochromes and to utilize each neuronal-like cell as
its own control, we decided to test three different neurite tracing approaches. First, we
traced each MDNC in its entirety using a semi-automated method. Since this approach is
lengthy, we also tested a simplified version in which only the longest primary neurite and
longest secondary neurite were traced. Finally, the third and most intriguing alternative
was to use an automated method without the addition of a fluorochrome. Automated
software are triggered by brightness. Neuronal-like cells appear significantly brighter than
the background when pictures are taken using light microscopy, and thus, cell recognition
is expected.
The first goal of this study was to compare the expression of several previously
unreported neuronal markers between MDNCs, human neuroblastoma cells and THP-1
cells (a human monocytic cell line) to further validate MDNCs as neuronal-like cells. The
second and main objective was to determine which of the three neurite tracing methods was
faster. We hypothesized that an automated method would be faster than the other two semiautomated approaches. The third and final goal was to establish whether any of the
three techniques was better at exposing neurostructural defects, with the expectation that
whole-cell tracing of MDNCs would reveal the highest number of structural deficiencies,
considering the thoroughness of this approach.
2. Methods
2.1. Cell Culture
All blood donors gave their informed and written consent after receiving a full description of the study. Experiments were approved by the Institutional Review Board (IRB) at
Penn State University (Study #00006911). Fresh blood was obtained from healthy individuals. We then followed our transdifferentiation protocol, as previously described [28]. Briefly,
fresh blood was separated into its components by Ficoll-Paque (17-1440-03, GE Healthcare,
Chicago, IL, USA). A fraction of peripheral blood mononuclear cells (PBMCs) was cultured
on fibronectin-coated 25 cm2 flasks (13.5 million PBMCs per flask). The remaining PBMCs
were used for isolation of CD14+ cells (monocytes) by positive immunomagnetic selection
based on the manufacturer protocol (CD14 human microbeads, 130-050-201 Miltenyi Biotec,
Auburn, CA, USA). CD14+ cells were cultured on fibronectin-coated wells at a concentration of 180,000 cells per cm2 . Plastic plates and flasks came from BD Falcon, Glendale, AZ,
USA (351146, 353043 and 353109). Human fibronectin from plasma (F2006, Sigma-Aldrich,
St. Louis, MO, USA) was used at a concentration of 20 µg/mL, and coating was carried
out overnight at 4 ◦ C. Macrophage colony-stimulating factor (MCSF) from AbCys, Paris,
France (300-25) was added to monocytes right before culturing at a final concentration of
50 ng/mL (Figure 1A). All cells were maintained in Dulbecco’s modified Eagle medium
(DMEM), high glucose, GlutaMAX (61965059, GIBCO, Waltham, MA, USA), in which we
added 100 U/mL penicillin; 100 mg/mL streptomycin, 1% nonessential amino acids, 1 mM
sodium pyruvate, 10 mM HEPES buffer, (all from Life Technologies, Waltham, MA, USA)
and supplemented with 10% fetal bovine serum (FBS) Performance Plus from GIBCO
(Waltham, MA, USA). Cell culture medium was then replaced on days 4, 7, 10 and 13, as
described in Figure 1. The following chemicals and growth factors were added, as shown
in Figure 1: butylated hydroxyanisole (BHA) (B1253, Sigma-Aldrich, St. Louis, MO, USA),
retinoic acid (RA) (R2625, Sigma-Aldrich, St. Louis, MO, USA), insulin growth factor-1
(IGF-1) (100-11, PeproTech, Cranbury, NJ, USA) and neurotrophin-3 (NT-3) (450-03-100,
Peprotech, Cranbury, NJ, USA). On day 17, cell culture media was not replaced; instead,
25 mM potassium chloride (KCL) was added (P5405, Sigma-Aldrich, St. Louis, MO, USA).
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Pictures of cells were taken using a Nikon (Melville, NY, USA) Eclipse Ti-S/L 100 inverted microscope equipped with a CoolSNAP Myo, 20 MHz, 2.8 Megapixel, 4.54 × 4.54 µm
pixels camera (Melville, NY, USA) and with a Nikon CFI Super flour 20X DIC prism objective (Melville, NY, USA). Pictures were taken immediately after monocyte extraction and
on days 20–21 when transdifferentiation was completed (Figure 1B). Pictures of transdifferentiated cells either under control conditions or after treatment with colchicine 0.5 µM
(Sigma-Aldrich, C9754) were identified via a micro-ruled coverslip (Cellattice CLS5-25D,
Nexcelom Bioscience, Lawrence, MA, USA). Only neuronal-like cells with at least one primary neurite longer than 2 times the soma size before treatment were traced.
Immunofluorescence was performed as previously described [28] (f. Briefly, after
fixation and permeabilization, cells were stained with 40 ,6-diamidino-2-phenylindole,
dihydrochloride (DAPI, D1306, Thermo Fisher Scientific, Waltham, MA, USA), mouse antitubulin (1/100, Invitrogen, Waltham, MA, USA), Alexa Fluor-488 (1/200, Life Technology,
Waltham, MA, USA) and rhodamine phalloidin (1/200, Invitrogen, Waltham, MA, USA).
Images were visualized with a Leica DMI 6000 microscope (Wetzlar, Germany) equipped
with a Micro MAX-1300YHS camera using an HCX PL APO 60X oil objective (Leica, Wetzlar,
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Germany). Images were captured using Metamorph Software (Version 7.1.3, Molecular
Devices, San Jose, CA, USA).
2.2. Single Cell RNA-Sequencing
We utilized microfluidic single-cell capture and single-cell mRNA sequencing technologies via Fluidigm’s C1TM Single-Cell Autoprep System (C1) to explore genome-wide
gene expression in 17 cells exposed to our transdifferentiation protocol and for THP-1 cells.
We followed the manufacturer’s protocol, as previously described [28]. In short, cells were
loaded using an integrated fluidic circuit (IFC) chip that allowed capturing a single cell
per well. After optical confirmation of cell number at each capture site on the chip, the
cells were processed for in-line cell lysis, reverse transcription and cDNA amplification
steps. The resulting cDNA was converted to a sequencing library using Illumina’s Nextera
XT library preparation kit. The Rapid mode of Illumina HiSeq 2500 was used to generate
sequencing reads of sufficient depth (about 3 million of sequencing reads) per each cell. Demultiplexed sequencing reads passed the default quality filtering of the Illumina CASAVA
pipeline (v1.8, Ilumina, Inc., San Diego CA, USA) and were then exposed to further quality
trimming/filtering using FASTX-Toolkit (v.0.0.13, Hannon Laboratory, Cold Spring Harbor,
NY, USA). The filtered reads were aligned to the most recent reference genome (hg38) using
Tophat (v2.0.9, Center for Computational Biology, Baltimore, MD, USA) [36] by allowing
up to 2 mismatches. After normalization was performed via the median of the geometric
means of fragment counts across all libraries, fragments per kilobase per million (FPKM)
mapped reads values were calculated using Cuffdiff tool, which is available in Cufflinks
version 2.2.1 (Trapnell Lab, Seattle, WA, USA) [37]. Some results from this experiment were
reported previously [28], but the expression of all genes presented in this manuscript have
never before been reported in MDNCs.
Gene expression for human neuroblastoma cells was obtained from a public database
generated by Li et al. [38].
2.3. Statistical Analysis
The non-parametric Mann–Whitney test was used to make pairwise comparisons
between MDNCs treated with colchicine versus MDNCs under control conditions. A oneway ANOVA followed by Bonferroni correction was used to make comparisons between
the time it took to trace MDNCs using each of the three tracing methods tested. p values
lower or equal to 0.05 were considered significant.
3. Results
3.1. Neuronal and Monocyte Markers in MDNCs, SH-SY5Y and THP-1 Cells
We compared the expression of 12 neuronal markers between (a) MDNCs; (b) SHSY5Y cells, a human neuroblastoma cell line commonly used to study neuronal processes;
and (c) THP-1 cells, a human monocytic cell line (to serve as negative control). Of the
12 neuronal markers, 7 are involved in synaptic functions, 4 are part of the neuronal
structure and one is a gamma-aminobutyric acid (GABA) type A receptor (Table 1). The
expression of these 12 genes has never been reported in MDNCs. Expression of these
12 genes in 17 MDNCs was determined by single-cell mRNA sequencing. All 12 neuronal
markers were expressed in at least one MDNC, and most genes were expressed in at
least 6 MDNCs (Table 2). SH-SY5Y cells also expressed all of these neuronal genes, while
they were not expressed in THP-1 cells (Table 2). We then tested whether two markers
for monocytes were present in THP-1 cells, MDNCs or SH-SY5Y. As expected, these
two monocyte-specific genes were highly expressed by THP-1 cells, whereas they were
not expressed by undifferentiated neuroblastoma cells and were barely detectable in
differentiated SH-SY5Y cells (Table 2). Only 1 out of the 17 MDNCs showed very low
expression of 1 monocyte marker, and none were expressed in the remaining 16 MDNCs
(Table 2).
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Table 1. Neuronal and monocytic genes and their functions.
Protein

Gene

Identifier

Function

Reference

Neurexin 3
Synaptosome-associated protein 25
Synaptic vesicle glycoprotein 2A
Vesicle-associated membrane
protein 1
SH3 and multiple ankyrin repeat
domains 2
Synuclein alpha
Syntaxin 1A

NRXN3
SNAP25
SV2A

ENSG00000021645
ENSG00000132639
ENSG00000159164

Synapsis
Synapsis
Synapsis

VAMP1

ENSG00000139190

Synapsis

Sudhof 2021 [39]
Antonucci et al. 2016 [40]
Nowack et al. 2010 [41]
Bhattacharya et al.
2002 [42]

SHANK2

ENSG00000162105

Synapsis

Lim et al. 1999 [43]

SNCA
STX1A

ENSG00000145335
ENSG00000106089

Synapsis
Synapsis

Spire type actin nucleation factor 1

SPIRE1

ENSG00000134278

Neuronal structure

Microtubule-associated protein tau

MAPT
SHTN1
(KIAA1598)
GAP43

ENSG00000186868

Neuronal structure

Burre 2015 [44]
Bennett et al. 1992 [45]
Schumacher et al,
2004 [46]
Barbier et al. 2019 [47]

ENSG00000187164

Neuronal structure

Toriyama et al. 2006 [48]

ENSG00000172020

Neuronal structure

Meiri et al. 1986 [49]

GABRB3

ENSG00000166206

GABA receptor

Mortensen et al. 2010 [50]

ITGAM

ENSG00000169896

Immune system

Schmid et al. 2018 [51]

CCR2

ENSG00000121807

Immune system

Tu et al. 2020 [52]

Shootin 1
Growth-associated protein 43
Gamma-aminobutyric acid (GABA)
type A receptor subunit beta 3
Integrin subunit alpha M
CD11B
Monocyte chemoattractant protein
1 peceptor

Table 2. Expression of 12 neuronal markers and 2 markers for monocytes in THP-1 monocytic cells, SH-SY5Y neuroblastoma
cells and 17 MDNCs.
Gene

THP1

NRXN3
0
SNAP25
0
SV2A
0
VAMP1
0
SHANK2 0
SNCA
0
STX1A
0
SPIRE1
0
MAPT
0
SHTN1
0
GAP43
0
GABRB3
0
ITGAM 14.91
CCR2
24.62

1
0
0
0
0
0
5.35
0
27.2
0.089
45.73
0
0.324
0
0

2
0
0
0
0
0
8.08
0
58.02
0.023
25.8
0
0.458
0
0

3
0.101
0.779
0.089
0
0
0
0
0.292
0
4.66
0
0.065
0
0

4

5

3.106
0.167
0
0
0
0
0
5.19
0
0.27
0.211
0.254
0
0

0.04
0.13
0
0.256
0.132
0.811
0
0
0.075
4.62
0
0.247
0
0

6
0.012
0.219
0
0
0.031
1.12
0.028
0.01
0.192
2.47
0
0.079
0
0

7

8

9

10

11

12

13

14

15

16

17

SHSY5Y
1*

SHSY5Y
2*

0
0.401
0
0
0
0
0
0
0.024
43.59
0
0.095
0
0

0.009
0
0
0
0.76
0
0
16.34
0.128
4.53
0
0.21
0
0

0
0
0.127
0
0.068
0
0
0.223
0
16.44
0
0.13
0
0

0.288
0
0.044
0.692
0.929
0
0
3.37
0.045
20.04
0
0.06
0
0

0
0
0
0
0
0
0
0
0.042
0
0
0.225
0
0

0
1.19
0
0
0.059
276.9
0
0
0.028
0
0
0
0.034
0

0.062
0.288
0
0
0
0
0
17.32
0
1.36
0
1.06
0
0

0.061
0
0.086
0.054
0.223
0
0
28.61
0
12.95
0
0.093
0
0

0.022
0
0.171
0
0.552
136.3
0
110.5
0.019
0.154
0
0.901
0
0

0
0.171
0
0
0
1.63
0
2.85
0.032
0
0
0.173
0
0

0.98
0
0.055
0
0.199
0
0
23.25
0.073
83.34
0
0.182
0
0

0.01
25.06
10.37
0.942
0.219
3.776
8.742
9.341
1.535
2.038
62.16
10.25
0
0

0.135
42.23
6.810
1.472
0.229
7.513
9.759
6.986
4.176
3.827
86.84
9.763
0.014
0.078

1 * undifferentiated SH-SY5Y; 2 * differentiated SH-SY5Y; data from Li et al. 2015 [38].

3.2. Whole-Cell Tracing
After 20 days in culture following our protocol [28], transdifferentiated monocytes
acquired a neuronal morphology comparable with that of HDNs (Figure 1B). These MDNCs extended neurites with a microtubule-based shaft, as shown in Figure 1C. Colchicine
is well-known for its ability to elicit neurite retraction [53,54] via microtubule depolymerization [55]. In a prior publication, we showed that the structure of MDNCs responds
similarly to the structure of neuroblastoma cells and that of human neurons in vitro when
treated with colchicine 0.5 µM [28]. While retraction is expected with colchicine 0.5 µM,
minimal to no retraction should occur under control conditions. To determine whether
MDNCs exhibited any retraction under control culture conditions, a group of MDNCs was
identified and photographed at baseline, meaning at time zero (T0 h). These MDNCs were
kept under control conditions for 1 h (T1 h), and pictures of the exact same MDNCs were
taken again (Figure 2A). The same procedure was followed to establish whether colchicine
elicited pruning of neuronal extensions. In this latter case the 1 h incubation period was
carried out in the presence of colchicine 0.5 µM (Figure 2A).
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110 ± 6%; p = 0.22) (Figure 2B). To establish differences in the number of neurites pruned,
we subtracted the number of neurites at T0 h from the number of neurites at T1 h for
MDNCs cultured under control conditions as well as for cells treated with colchicine 0.5
µM. Whole-cell tracing did not reveal differences in the number of primary (CTL, 0.14 ±
0.12; Colchi, 0.18 ± 0.16; non-parametric analysis p = 0.48), secondary (CTL, 1.06 ± 0.4; Col8 of 16
chi, 1.2 ± 0.4; p = 0.45), tertiary (CTL, 0.010 ± 0.11; Colchi, 0.073 ± 0.14; p = 0.52) or total
neurites pruned (CTL, 1.25 ± 0.43; Colchi, 1.46 ± 0.45; p = 0.27) (Figure 2B).
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(B) Bar graphs comparing MDNCs’ structural response to colchicine versus MDNCs under control
conditions. Structural parameters include longest primary neurite (LPN), longest secondary neurite
(LSN), number of primary neurites, number of secondary neurites, number of tertiary neurites and
total number of neurites. Data are presented as mean ± SEM. Differences were assessed using the
non-parametric Mann–Whitney test. For LPN, number of primary, number of secondary, number of
tertiary and total number of neurites, n = 96 for control and n = 82 for colchicine. For LSN, n = 91 for
control and n = 75 for colchicine. * p = or < 0.05.

The principal investigator (PI), who has ample experience tracing cells, traced these
four sets of MDNCs, meaning cells that were cultured under control conditions at T0 h
and T1 h, as well as cells treated with colchicine at T0 h and T1 h. Since the entire neuropil
of each MDNC was traced, we can report differences in the longest primary neurite
(LPN), longest secondary neurite (LSN), number of primary neurites, number of secondary
neurites, number of tertiary neurites and total number of neurites. MDNCs were traced
using a semi-automated software called FIJI (NIH, Bethesda, MD, USA), which is a plugin
for ImageJ, an open source image processing program provided by the National Institutes
of Health (NIH).
To determine whether there was retraction of LPN or LSN, the percentage of neurite
remaining at T1 h was calculated (T1 h/T0 h) for MDNCs cultured under control conditions, as well as cells treated with colchicine 0.5 µM. Then, non-parametric statistical
analyses were conducted to establish whether there were differences between control (CTL)
and colchicine (Colchi). Whole-cell tracing by the PI evidenced a statistically significant
reduction in the percentage of LPN after treatment with colchicine 0.5 µM (CTL, 99 ± 2%;
Colchi, 86 ± 2%; p = 0.0006), while there were no differences in LSN (CTL, 120 ± 8%; Colchi,
110 ± 6%; p = 0.22) (Figure 2B). To establish differences in the number of neurites pruned,
we subtracted the number of neurites at T0 h from the number of neurites at T1 h for MDNCs cultured under control conditions as well as for cells treated with colchicine 0.5 µM.
Whole-cell tracing did not reveal differences in the number of primary (CTL, 0.14 ± 0.12;
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Colchi, 0.18 ± 0.16; non-parametric analysis p = 0.48), secondary (CTL, 1.06 ± 0.4; Colchi,
1.2 ± 0.4; p = 0.45), tertiary (CTL, 0.010 ± 0.11; Colchi, 0.073 ± 0.14; p = 0.52) or total
neurites pruned (CTL, 1.25 ± 0.43; Colchi, 1.46 ± 0.45; p = 0.27) (Figure 2B).
3.3. Three Neurite Tracing Approaches
Three neurite tracing approaches were tested by four individuals with research experience (two medical students with previous research experience, one neuroscience graduate
student and one laboratory technician). One of the medical students had performed cell
tracing before participating in this study, whereas all other participants had no experience
in tracing. The tracers were blinded to the treatment condition each of the two groups
of MDNCs had received (either CTL or Colchi), and they were unaware of that we were
expecting pruning of neuronal extensions with Colchi. Participants were trained on how to
use FIJI (NIH, Bethesda, MD, USA), a semi-automated software, and Volocity (Quorum
Technologies, Ontario, Canada), an automated software. After training was completed,
participants were told to use FIJI for whole-cell tracing, and they were instructed to trace
all neurites present in MDNCs for this first tracing method. For the second tracing method,
they were again instructed to use FIJI, but this time to trace only the longest primary and
longest secondary neurite in each of the MDNCs. This second approach was named the
longest neurite method (LN). For the third method, participants processed the photographs
of MDNCs for each of the two treatment conditions through Volocity and then confirmed
that the MDNCs had been traced. Finally, participants were asked to record the time it took
them to trace MDNCs with each of the three tracing methods.
Volocity automatically traces the length and width of the cell, which in the case of
neuronal-like cells approximates to the longest primary neurite and the longest secondary
neurite. Since two of the three tracing methods tested only provided information on
LPN and LSN, we compared the three tracing approaches based on these two neuronal
extensions. None of the four individuals encountered any statistically significant difference
in LPN after whole-cell tracing (participant 1 (P1), CTL, 95 ± 2%; Colchi, 100 ± 3%; p = 0.35;
P2, CTL, 100 ± 5%; Colchi, 100 ± 2%; p = 0.86; P3, CTL, 100 ± 2%; Colchi, 99 ± 2%, p = 0.44;
P4, CTL, 99.9 ± 2.8%; Colchi, 100 ± 4.6%; p = 0.45) (Figure 3A). Participant 3, however,
found colchicine elicited a statistically significant retraction of LSN (P3, CTL, 118 ± 10.3%;
Colchi, 88.1 ± 9.7%; p = 0.004), while all other participants observed no differences (P1, CTL,
97 ± 12.4%; Colchi, 109.9 ± 11.3%; p = 0.24; P2, CTL, 100.6 ± 9.5%; Colchi, 88.9 ± 6.2%;
p = 0.27; P4, CTL, 104.5 ± 10%; Colchi, 100.1 ± 7.5%; p = 0.71) (Figure 3A).
When tracing only longest neurites, one of the participants found colchicine elicited
a statistically significant retraction of LPN when compared with MDNCs under control
conditions (P2, CTL, 100 ± 4%; Colchi, 90 ± 2%; p = 0.04) (Figure 3B). All other participants
found no statistical differences in LPN (P1, CTL, 93 ± 4%; Colchi, 92 ± 3%; p = 0.66; P3, CTL,
95 ± 4%; Colchi, 100 ± 3%; p = 0.34; P4, CTL, 91.7 ± 2.7%; Colchi, 91.4 ± 3.4%; p = 0.42).
The same participant who found a significant retraction of LSN while tracing the entire cell
again encountered retraction elicited by colchicine while tracing only longest neurites (P3,
CTL, 143.2 ± 15.8%; Colchi, 84.6 ± 7%; p = 0.001) (Figure 3B). Two other participants found
no statistical differences in LSN (P1, CTL, 100 ± 14.9%; Colchi, 119.7 ± 16.3%; p = 0.07; P2,
CTL, 100.7 ± 7.8%; Colchi, 116.2 ± 17.1%; p = 1.0), and one participant did not trace LSN
(Figure 3B).
The use of Volocity rendered no statistically significant differences in LPN for any of
the participants (P1, CTL, 90.2 ± 5.5%; Colchi, 81.4 ± 11%; p = 0.14; P2, CTL, 94.6 ± 9.6%;
Colchi, 120.7 ± 17.4%; p = 0.18; P3, CTL, 95 ± 6.4%; Colchi, 91.7 ± 5.7%, p = 0.68; P4, CTL,
116.6 ± 18.2%; Colchi, 92.2 ± 11.8%; p = 0.27) (Figure 3C). However, participant 4 found
a significant retraction in LSN after treatment with colchicine (P4, CTL, 156.2 ± 18.4%;
Colchi, 117 ± 20.3%; p = 0.05) (Figure 3C). None of the other participants found statistical
differences in LSN while using Volocity (P1, CTL, 202.5 ± 25.5%; Colchi, 182.9 ± 33.6%;
p = 0.27; P2, CTL, 148.6 ± 16.1%; Colchi, 173 ± 38.5%; p = 0.99; P3, CTL, 121.2 ± 12%;
Colchi, 119.4 ± 16.4%; p = 0.31) (Figure 3C).
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0.00001) (Figure 3D). Bonferroni correction indicated that tracing longest neurites (LN)
took less than half of the time needed to trace the whole cell (WC) (LN, 77.8 ± 8.5 min; WC,
153.6 ± 17.9 min; p = 0.001), while tracing the entire cell was more efficient than using
Volocity (WC, 153.6 ± 17.9 min; V, 332.5 ± 39.9 min; p = 0.001) (Figure 3D). Since one of the
students did not trace longest secondary neurites when applying the LN approach, we
ran another one-way ANOVA excluding that individual’s LN data. The results remained
significant (F(2, 19) = 20.81, p = 0.00001).
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(C) Bar graphs comparing MDNCs’ structural response to colchicine versus MDNCs under control
conditions after tracing MDNCs’ length and width using the automated tracing software Volocity.
The statistical assessment and data presentation are the same as in (A). P1: for LPN n = 30 for control
and n = 26 for colchicine; for LSN, n = 30 for control and n = 23 for colchicine. P2: for LPN n = 25
for control and n = 18 for colchicine; for LSN, n = 25 for control and n = 18 for colchicine. P3: for
LPN n = 33 for control and n = 30 for colchicine; for LSN, n = 33 for control and n = 30 for colchicine.
P4: for LPN n = 27 for control and n = 24 for colchicine; for LSN, n = 27 for control and n = 24 for
colchicine. * p = or < 0.05. (D) Dot plot comparing the time in minutes necessary for completing
the tracing of all MDNCs (control + colchicine) with each of the three tracing methods: whole cell,
longest neurite and Volocity. Data are presented as mean ± SEM. Differences were assessed using a
one-way ANOVA followed by Bonferroni correction. For whole cell, longest neurite and Volocity
n = 8. * p < 0.005, ** p < 0.002 and *** p < 0.00002.
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A one-way ANOVA revealed that the amount of time necessary to complete all
tracings was significantly different between each of the three approaches (F(2, 21) = 25.74,
p < 0.00001) (Figure 3D). Bonferroni correction indicated that tracing longest neurites (LN)
took less than half of the time needed to trace the whole cell (WC) (LN, 77.8 ± 8.5 min;
WC, 153.6 ± 17.9 min; p = 0.001), while tracing the entire cell was more efficient than using
Volocity (WC, 153.6 ± 17.9 min; V, 332.5 ± 39.9 min; p = 0.001) (Figure 3D). Since one of
the students did not trace longest secondary neurites when applying the LN approach, we
ran another one-way ANOVA excluding that individual’s LN data. The results remained
significant (F(2, 19) = 20.81, p = 0.00001).
4. Discussion
We have previously shown that MDNCs conduct electrical activity and express a wide
variety of neuronal markers [28]. Here we expanded the list to include 12 neuronal genes:
7 involved in synaptic transmission [39–45], 4 associated with neuronal structure [46–49]
and 1 gamma-aminobutyric acid (GABA) receptor [50] (Tables 1 and 2). Several of these
genes are implicated in the pathophysiology of neurodevelopmental illnesses. For instance,
neurexin 3 has been linked to autism [56], whereas SV2A and VAMP are associated with
schizophrenia [57,58]. Another synaptic gene, SNAP-25, has been implicated in the etiology
of both illnesses [59,60]. Tau and GAP-43 are essential for the development of neuronal
structure [47,49]. While tau is commonly known for its association with Alzheimer’s
disease, this protein has also been linked to schizophrenia [61]. Similar to tau, GAP-43 is
crucial for outgrowth of neuronal extensions [49], and not surprisingly, abnormalities in the
expression of GAP-43 have been associated with both schizophrenia [62] and autism [63].
Other proteins relevant for the establishment of neuronal shape during development and
often involved in the pathophysiology of schizophrenia, such as MAP-2 [64,65], are also
expressed by MDNCs [28]. At the same time, markers for monocytes such as CD11B and
CCR2 [51,52] are no longer present in MDNCs (Tables 1 and 2).
Several lines of evidence strongly indicate that deficits in the neuronal structure are
implicated in the pathophysiology of autism and schizophrenia [12,13,66–68]. However,
the inaccessibility of neurons coming directly from living patients’ brains has limited the
study of early neurodevelopmental processes that transform neuronal structure. MDNCs
not only express a variety of genes crucial in sculpting neuronal shape, but in addition, the
structure of MDNCs is comparable with that of human neurons after 5 days in culture and
also with that of differentiated human neuroblastoma cells [28]. Moreover, the structure of
MDNCs responds similarly to that of neurons and neuroblastoma cells when treated with
dopamine and colchicine [28].
MDNCs’ ability to reproduce characteristics of the structure of human neurons opens
the opportunity for studying these aspects of neurodevelopmental illnesses directly in
living patients’ cells. This means that MDNCs provide a window into early neurodevelopmental processes in vitro, even when patients are already adults. Nonetheless, in order
to maximize the delivery of neurostructural results, it is imperative to determine which
neurite tracing method is more efficient in extracting data from MDNCs.
Unfortunately, there is no universal tracing method that can efficiently extract neurostructural data under all research conditions. Instead, experts recommend testing several
tracing approaches to determine which is the best suited for each laboratory [69,70]. Currently, there is a plethora of automated tracing methods, but the gold standard continues to
be manual tracing via semi-automated approaches [69]. Therefore, here we tested three different tracing approaches: (1) whole-cell tracing, (2) longest neurite tracing and (3) Volocity.
The first two are semi-automated and thus require more work, while the third method is
completely automated. However, before comparing these three tracing methods, we had to
establish the right conditions for comparison. Therefore, the principal investigator, who has
ample experience tracing cells, traced two separate groups of MDNCs: one cultured under
control conditions and one treated with colchicine 0.5 µM. This compound is well-known
for its capacity to cause neurite retraction via microtubules depolymerization [55]. Further-
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more, we have previously shown that colchicine elicits pruning of neuronal extensions in
MDNCs in a way similar to what is found in neurons [53] and neuroblastoma cells [54].
Using the more thorough tracing approach—namely, whole-cell tracing—the PI found
that colchicine elicited, as expected, a statistically significant retraction of LPN (Figure 2B).
None of the other structural parameters revealed statistical differences (Figure 2B). Then,
four other individuals, mostly students with research backgrounds, traced the same
two groups of MDNCs (control versus colchicine 0.5 µM) using the three different tracing
methods. These four participants were blinded to the treatment condition they were tracing.
All the statistically significant retractions found by these four participants were, as expected,
caused by colchicine (Figure 3A–C). However, relatively few structural differences were
found. This is not entirely surprising, as these four individuals had limited experience with
tracing, and the differences between the two MDNCs groups were subtle (Figure 2B). It
is important to note that the tracing approach that yielded more statistically significant
findings was the simplest of all, meaning the approach that only traced the longest primary
and longest secondary neurite (Figure 3B).
The most surprising finding was that Volocity, the automated tracing method, was
the slowest in delivering structural results (Figure 3D). This delay was not due to lack of
recognition of MDNCs, even though these cells were not marked with a fluorochrome.
Instead, pictures of MDNCs were live. The difficulties arose because in many instances
Volocity did not identify the entire neuritic length. Students, therefore, had to piece together
sections of neurites, similar to what other research teams have described using different
automated softwares [70]. This task was more time consuming than even tracing the
entire cell using a semi-automated approach (Figure 3D). Having MDNCs stained with
a fluorochrome would have eliminated the need for reconstruction of the neuritic length.
However, given the inherent damage attached to cell fixation and permeabilization [34,35],
it is questionable whether the subtle structural differences between control MDNCs and
those treated with colchicine would have been observed.
The fastest tracing approach was tracing only the longest primary and longest secondary neurites (Figure 3D). This approach was also the one that yielded more statistically
significant differences between treatment conditions (control versus colchicine 0.5 µM)
(Figure 3B). We were expecting whole-cell tracing to detect more structural differences,
given the precision of this method. However, perhaps the simplicity of tracing only
two neurites per MDNC as opposed to delineating the entire neuropil improves accuracy.
Given that tracing longest neurites was more accurate and took half the time as tracing the
entire cell and a quarter of the time as Volocity (Figure 3D), we recommend this tracing
approach for future studies on the structure of MDNCs.
There are other factors that need to be considered when selecting a tracing approach.
One is that tracing only the longest neurites neglects other structural parameters. Additionally, Volocity is just one of the many commercially available automated software products.
It is possible that other automated applications would recognize the entire structure of
MDNCs, even when analyzing photographs of live cells using light microscopy. However,
if automated software products become a viable alternative, cost will have to be factored
in, as semi-automated methods usually do not bear any cost to the researcher, while most
automated software have to be purchased [69,70].
In summary, selecting a tracing method is a complicated process that depends on
the specific research conditions to be tested [69,70]. For instance, analyzing neurons in
culture (2-dimensional) versus brain slices (3-dimensional) or studying intact neurites
versus damaged neurites would each generate its own set of intricacies for which only a
couple of tracing approaches would be suitable. It is also essential to determine which
aspects of the neuronal structure will be studied, as some tracing paradigms are better
at measuring neurite length, while others excel at counting number of extensions [69,70].
Therefore, experts recommend testing different tracing approaches to determine the most
efficient method for each laboratory [69,70]. Here, we determined that the most efficient
tracing strategy for studying neuritic length in MDNCs is tracing only the longest primary
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and longest secondary neurites (Figure 3D). The limitation of this modality is that it does
not provide information about the number of neurites or other aspects of the neuropil, such
as number or length of tertiary or quaternary neurites. Another limitation of our study is
that we only conducted tracing using one automated method among the many currently
available [69,70]. Future studies will have to be conducted to determine whether other
automated paradigms prove better at extracting neurostructural data from MDNCs.
5. Conclusions
MDNCs express a wide variety of neuronal markers that have been associated with
the pathophysiology of autism and schizophrenia. Since MDNCs originate from a blood
sample taken directly from patients, these cells carry the genetic susceptibility to the neurodevelopmental illness that the patients are afflicted with. In contrast with rodent neurons
in culture or neuronal cell lines such as neuroblastoma cells, MDNCs allow researchers to
study directly in patients’ cells early neurodevelopmental processes involving changes in
neuronal structure. In order to maximize efficiency in studying MDNCs’ structure, the best
approach is to only trace the longest primary neurite and the longest secondary neurite
using FIJI, a semi-automated software made available by the NIH.
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